Anales RANF

María Molinero Muñoz, José Manuel Martínez Sesmero, Francisco José Sánchez-Muniz @Real Academia Nacional de Farmacia. Spain 180 adverse interactions: types, identification and update. An Real Acad Farm. 2018;84(2):216-25. 11. Jianyuan D, Xiao Z, Zongmeng C, et al . A review of food–drug interactions on oral drug absorption. Drugs. 2017;77(17):1-16. 12. Briguglio M, Hrelia S, Malaguti M. et al. Food bioactive compounds and their interference in drug pharmacokinetic/pharmacodynamic profiles. Pharmaceutics. 2018;10(4):277. 13. Amidon GL, Lennernas H, Shah VP. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–20. 14. Benet LZ. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J Pharm Sci. 2013;102(1):1-3. 15. Benet LZ, Broccatelli F, Oprea IT. BDDCS applied to over 900 drugs. The AAPSS journal. 2011;13:520-21. 16. Guidance for industry: food-effect bioavailability and fed bioequivalence studies. U.S. Department of health and human services food and drug administration center for drug evaluation and research. 2002;2-4. 17. Herbrink M, Nuijen B. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treatment Rev. 2015; 41:412–22. 18. Aldaz Pastor A, Arocas Casañ V, Delgado Sánchez O. et al. Introducción a las interacciones farmacológicas. Sociedad Española de Farmacia Hospitalaria. 2012; 15-7. 19. Santana Martínez S, Marcos Rodríguez JA. et al. Oral chemotherapy: food-drug interactions. Farm Hosp. 2015; 39:203-9. 20. Koch KM, Reddy NJ, Cohen RB. et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol. 2009;27:1191–6. 21. Frederik E. Stuurman, Nuijen B, Beijnen JH. et al. Oral anticancer drugs: mechanism of low bioavailability and strategies for improvement. Clin Pharmacokinet. 2013; 52:399-414. 22. Van Leeuwen RW, Peric R, Hussaarts KG. et al. Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2016; 34:1309-14. 23. Frye RF, Fitzgerald SM, Lagattuta TF. et al. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol. 2004; 24:1508-14. 24. Fraga Elenes RA, Gordillo Bastidas D. Nutrición alternativa: efecto molecular de los suplementos. En: Nutrición molecular. Gordillo Bastidas D, Gordillo Bastidas E. (eds). McGraw Hill Education. Mexico. 2015, pp. 450-71. 25. Flores Balcázar CH. Cáncer: regulación molecular con componentes dietéticos. En: Nutrición molecular. Gordillo Bastidas D, Gordillo Bastidas E. (eds). McGraw Hill Education. Mexico. 2015, pp. 307-28. 26. Bilgi N, Bell K, Ananthakrishnan AN. et al. Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. Ann Pharmacother. 2010; 44(5):926-8. 27. Sánchez Muniz F. Efectos nutracéuticos e interacciones con medicamentos del ajo. An Real Acad Farm. 2018. 30-4. 28. Tarumoto T, Nagai T, Ohmine K. et al . Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib- resistant cell line. Exp Hematol. 2004; 32:375-81. 29. Lee KE, Hahm E, Bae S. et al. The enhanced tumor inhibitory effects of gefitinib and L-ascorbic acid combination therapy in non-small cell lung cancer cells. Oncol Lett. 2017; 14:276-82. 30. Van Erp NP, Baker SD, Zandvliet AS et al. Marginal increase of sunitinib exposure by grapefruit juice. Cancer Chemother Pharmacol. 2011; 67:695–703. 31. Fleisher B, Unum J, Shao J. et al. Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction. J Pharma Sci. 2015; 104:266-75. 32. Yin OQ, Gallagher N, Li A. et al. Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol. 2010; 50:188-94. 33. Velasco Martín A. Farmacología y toxicología del alcohol etílico o etanol. An Real Acad Med Cir Vall. 2014; 51:242-8. 34. Hernández Martín M. Relación entre el consumo de alcohol y el cáncer. Dialnet. 2018; 199-214. 35. Clugston RD, Blaner WS. The adverse effects of alcohol on vitamin A metabolism. Nutrients. 2012; 4:356-71. 36. Abbas R, Hug BA, Leister C. et al. A phase I ascending single-dose study for the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer Chemother Pharmacol. 2012; 69:221-7. 37. Devriese LA, Koch KM , Mergui-Roelvink M. et al. Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours. Invest New Drugs. 2014; 32:481-8. 38. Bai J, Shengyu Z, Fan X. et al. Inhibitory effects of flavonoids on P-glycoprotein in vitro and in vivo: Food/herb-drug interactions and structure-activity relationships. Toxicol Appl Pharmacol. 2019;369:49- 59. 39. Ramírez Tortosa MC, Camblor Álvarez M, García Peris P. Nutricón y cáncer. En: Tratado de Nutrición. Tomo mIV. Nutrición cínica. Gil A. (ed.). Editorial Médica Panamericana, Buenos Aires, 2020, pp. 547- 65. 40. Nishiyama M, Eguchi H. Recent advances in cancer chemotherapy: current strategies, pharmacokinetics, and pharmacogenomics. Adv Drug Deliv Rev. 2009; 20;61:367-8.